Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26), Zacks reports. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.

Theravance Biopharma Trading Up 1.2 %

NASDAQ TBPH traded up $0.11 on Wednesday, reaching $9.08. The company’s stock had a trading volume of 276,927 shares, compared to its average volume of 204,412. The business has a 50-day moving average price of $9.36 and a 200 day moving average price of $8.91. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90. The firm has a market cap of $446.50 million, a PE ratio of -8.99 and a beta of 0.21.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.75.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.